2023
Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial
McKee S, Lawrence D, Saccone P, McRae T, Anthenelli R. Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial. Drug And Alcohol Dependence Reports 2023, 8: 100177. PMID: 37520849, PMCID: PMC10372180, DOI: 10.1016/j.dadr.2023.100177.Peer-Reviewed Original ResearchNeuropsychiatric adverse eventsCessation outcomesContinuous abstinenceAdverse eventsPsychiatric cohortPsychiatric statusLower oddsEfficacy of vareniclineSmoking cessation medicationsPoint prevalence abstinenceHigher baseline levelsSex effectsLogistic regression modelsEAGLES trialCessation medicationsBaseline characteristicsSmoking historyMedication useNicotine patchPoint prevalenceStudy treatmentBaseline variablesBaseline cigarettesAbstinence outcomesSignificant interaction
2015
Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis
McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. Nicotine & Tobacco Research 2015, 18: 1002-1011. PMID: 26446070, PMCID: PMC5942618, DOI: 10.1093/ntr/ntv207.Peer-Reviewed Original ResearchConceptsSmoking cessation medicationsCessation medicationsSmoking cessationDouble-blind placebo-controlled trialEfficacy of vareniclinePlacebo-controlled trialShort-term outcomesClinical trial dataSex differencesSimilar ratesWeek 52Week 24Women smokersNicotine replacementWeek 12Outcome endpointsTherapeutic responseClinical trialsContinuous abstinenceVarenicline's efficacyVareniclinePlacebo outcomesEqual efficacySex disparitiesEffective FDA
2012
Longitudinal Associations Between Smoking Cessation Medications and Alcohol Consumption Among Smokers in the International Tobacco Control Four Country Survey
McKee SA, Young‐Wolff K, Harrison EL, Cummings KM, Borland R, Kahler CW, Fong GT, Hyland A. Longitudinal Associations Between Smoking Cessation Medications and Alcohol Consumption Among Smokers in the International Tobacco Control Four Country Survey. Alcohol Clinical And Experimental Research 2012, 37: 804-810. PMID: 23240586, PMCID: PMC3610791, DOI: 10.1111/acer.12041.Peer-Reviewed Original ResearchConceptsSmoking cessation medicationsCessation medicationsNicotine replacementAlcohol consumptionInternational Tobacco Control Four Country SurveyFour Country SurveyNicotine replacement therapyReduced alcohol consumptionSmoking statusReplacement therapySmoking cessationMedication effectsMedicationsSmoking behaviorEpidemiological investigationsCountry SurveySmokersAvailable evidenceLongitudinal associationsBaseline drinkingEpidemiological sampleFrequent drinkingTelephone surveyVareniclineSmokingDeveloping and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine & Tobacco Research 2012, 14: 1362-1371. PMID: 22492085, PMCID: PMC3482010, DOI: 10.1093/ntr/nts090.Peer-Reviewed Original ResearchConceptsSubsequent ad libitum smokingSmoking cessation medicationsAd libitum smokingCessation medicationsNicotine deprivationSmoking cessationNovel smoking cessation medicationsRatings of cravingSmoking lapse behaviorHuman laboratory modelSecondary outcomesClinical efficacyClinical findingsFirst cigaretteMedication effectsSmokingMedication developmentCigarette effectsMedicationsLapse behaviorSmoking lapseTranslational toolScreen medicationsMonetary reinforcementTranslational work